Across TCGA pan-cancer cohorts, ATF7IP2 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ATF7IP2 data layer compared with 22 for mass-spec protein and 5 for mutation status.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ATF7IP2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ATF7IP2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.
LUAD are the cancer types where ATF7IP2 mass-spec protein most reproducibly stratifies survival.